Treatment of COVID-19 with casirivimab/indevimab in a patient with cervical spine injury: A case report
Year: 2025
Type: article
Study design: Case Report
Abstract: Introduction/Aim: We present a patient suffering from COVID-19 with a cervical spine injury who was treated with the antiviral drug casirivimab/indevimab (Regen-CoV), monoclonal antibodies for COVID-19, during hospital treatment at the Batajnica Hospital of the University Clinical Center of Serbia. Case report: The administration of the drug casirivimab/indevimab (Regen-CoV) prevented the development of a more severe picture of Covid-19 and led to the rapid negativization of the nasopharyngeal swab for SARS-CoV-2 in our patient who had a cervical spine injury. The patient underwent successful cervical spine surgery at the Institute for Orthopedic-Surgical Diseases in Banjica, which led to the recovery of the neurological deficits he had previously. Conclusion: We showed another significant indication for using casirivimab/ indevimab (Regen-CoV) in hospital conditions, which was off-label according to therapeutic protocols.
DOI: 10.5937/smclk6-55371
Authors: Miljana Vrhovac, Tijana Stanišić, Milan Mirković, Jelena Veličković, Sead Dalifi, Danilo Jeremić, Filip Pilipović, Tatjana Adžić-Vukičević
Language: English
Subfield: Infectious Diseases
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
OpenAlex ID: W4409350192
